SOURCE: Burrill & Company

May 09, 2011 06:00 ET

Distinguished Scientist Speaks on Stem Cell Research Challenges and Opportunities at the Burrill Latin America Life Sciences Conference

SAN FRANCISCO, CA--(Marketwire - May 9, 2011) - Embryonic stem cell research designed to discover breakthrough treatments for cancer, Parkinson's, and Alzheimer's disease is active in Brazil, Mexico and Argentina thanks to supportive policies that encourage such innovation. Burrill & Company's inaugural Latin America Life Sciences Conference to be held May 19-20, 2011 in Rio De Janeiro, Brazil, will provide attendees insight into the current state of stem cell research and the challenges that must be overcome moving from the lab to the marketplace.

Dr. Hans Keirstead, associate professor at the University of California, Irvine, in a keynote address will discuss the hurdles faced in winning regulatory approval for the first human embryonic stem cell trial for spinal cord injury.

"We are delighted to have such a renowned scientist as Dr. Keirstead participate at our conference. The pace of stem cell research in Latin America is accelerating and this is opening up partnering and collaborative opportunities for global researchers and companies to work with scientists and research institutions in the region," says G. Steven Burrill, CEO, Burrill & Company.

Dr. Keirstead directs a research team investigating the cellular biology and treatment of spinal cord trauma, research that also has significance for other diseases of the nervous system. In particular, his focus is on stem cell therapies as they relate to spinal cord injury, spinal muscular atrophy, multiple sclerosis, and other diseases of the nervous system. He is the recipient of many awards and has also testified before the United States Senate and House of Representatives on multiple occasions regarding stem cell research and policy.

The two-day conference will feature the science, business, and investment opportunities that are unfolding from initiatives in Latin America. It will bring together CEOs, scientists, corporate executives, financiers, regulators, government officials, and academic leaders from around the world to discuss current state of life sciences with industry leaders in Latin America. The meeting provides an opportunity to gain an understanding of the emerging bio-based economy in Latin America, as well as access to thought leaders who will shape its future.

To register for this event and for additional information, visit

About Burrill & Company
Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With more than $1 billion in assets under management, the firm's businesses include venture capital, private equity, merchant banking, and media. By leveraging the scientific and business networks of its investment team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, management expertise, insight, market intelligence and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe and Asia. For more information visit:

Contact Information

  • Media Relations:
    Peter Winter